David M. Stern
47Patents
19h-index
37Co-inventors
81Inventor score
Filing activity: Dec 8, 1978 → Jan 13, 2011
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5552267A | Solution for prolonged organ preservation | Human Necessities | 111 | Expired |
| US5370989A | Solution for prolonged organ preservation | Human Necessities | 80 | Expired |
| US4485673A | Two-wire level measuring instrument | Physics | 56 | Expired |
| US6315995A | Methods for treating an ischemic disorder and improving stroke outcome | Chemistry; Metallurgy | 55 | Expired |
| US6316403A | Methods for treating an ischemic disorder and improving stroke outcome | Chemistry; Metallurgy | 54 | Expired |
| US5510779A | Error compensating instrument system with digital communications | Physics | 47 | Expired |
| US6825164B1 | Method to increase cerebral blood flow in amyloid angiopathy | Chemistry; Metallurgy | 40 | Expired |
| US6677299B2 | Method to increase cerebral blood flow in amyloid angiopathy | Chemistry; Metallurgy | 38 | Expired |
| US7101838B2 | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts | Human Necessities | 35 | Expired |
| US6670136B2 | Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof | Human Necessities | 34 | Expired |
| US5839443A | Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation | Physics | 33 | Expired |
| US5641867A | Antibody which specifically binds to endothelial-monocyte activating polypeptide II | Human Necessities | 33 | Expired |
| US6969704B1 | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject | Chemistry; Metallurgy | 31 | Expired |
| US4235106A | System and method for obtaining compensated level measurements | Physics | 30 | Expired |
| US5049878A | Two-wire compensated level measuring instrument | Physics | 29 | Expired |
| US6555651B2 | Ligand binding site of rage and uses thereof | Human Necessities | 29 | Expired |
| US6228837A | Endothelial monocyte activating polypeptide II: a mediator which activates host response | Human Necessities | 22 | Expired |
| US7258857B2 | Rage-related methods for treating inflammation | Human Necessities | 22 | Expired |
| US6391300B1 | Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation | Physics | 21 | Expired |
| US5426097A | Calreticulin: a novel antithrombotic agent | Emerging Cross-Sectional Technologies | 18 | Expired |
| US6268479A | Intracellular amyloid-beta peptide binding (ERAB) polypeptide | Chemistry; Metallurgy | 16 | Expired |
| US6465422B1 | Method for inhibiting tumor invasion or spreading in a subject | Human Necessities | 16 | Expired |
| US6555340B1 | Nucleic acid encoding bovine extracellular rage binding protein (en-rage) | Human Necessities | 15 | Expired |
| US6790443B2 | Method for treating symptoms of diabetes | Human Necessities | 14 | Expired |
| US6753150B2 | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage | Physics | 13 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.